Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems

Thorax

Volumn 55, Issue 9, 2000, Pages 731-735

  Edwards, J G ^a,b   Abrams, K R ^c   Leverment, J N ^a   Spyt, T J ^a   Waller, D A ^a   O'Byrne, K J ^b  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Malignant mesothelioma; Prognosis; Staging

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0033849171     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.9.731     Document Type: Article

References (29)

1. 1 Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
2. 2 Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
3. 3 Middleton G, Smith I, O'Brien M, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269-73.
4. 4 Steele J, Evans N, Shamash J, et al. Vinorelbine is effective palliative therapy for malignant mesothelioma: a phase II study. Br J Cancer 1999;80:65.
5. 5 Sterman DH, Kaiser LR, Albelda SM. Advances in the treatment of malignant pleural mesothelioma. Chest 1999; 116:504-20.
6. 6 Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997;52:507-12; erratum, 1997;52:1018.
7. 7 McLean AN, Patel KR. Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987-1992. Scott Med J3 1997;42:37-9.
8. 8 Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organisation for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-52.
9. 9 Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
10. 10 Sugarbaker DJ, Norberto JJ, Swanson SJ. Surgical staging and work-up of patients with diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997;9:356-60.
11. 11 Rusch V. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108:1122-8.
12. 12 Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-26.
13. 13 Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
14. 14 Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
15. 15 Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Ann Intern Med 1982;96:746-55.
16. 16 Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987;5:86-91.
17. 17 Alberts A, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35.
18. 18 Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
19. 19 Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988;93:159-62.
20. 20 Spirtas R, Connelly R, Tucker M. Survival patterns for malignant mesothelioma: the Seer experience. Int J Cancer 1988;41:525-30.
21. 21 Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7: 1157-68.
22. 22 Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8: 175-84.
23. 23 Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993;72:394-404.
24. 24 De Pangher Manzini V, Brollo A, Franceschi S, et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993;72:410-7.
25. 25 Fusco V, Ardizzoni A, Merlo F, et al. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients. Anticancer Res 1993;13:683-9.
26. 26 Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-8.
27. 27 Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997;182:211-6.
28. 28 Kumar-Singh S, Jacobs W, Dhaene K, et al. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998;186:300-5.
29. 29 Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.